Sujet(s)
Transfusion sanguine intra-utérine/méthodes , Érythème infectieux/thérapie , Anasarque foetoplacentaire/thérapie , Thérapie de rattrapage/méthodes , Échographie interventionnelle/méthodes , Échographie prénatale/méthodes , Adulte , Érythème infectieux/imagerie diagnostique , Érythème infectieux/embryologie , Femelle , Humains , Anasarque foetoplacentaire/imagerie diagnostique , Anasarque foetoplacentaire/épidémiologie , Grossesse , Résultat thérapeutiqueRÉSUMÉ
PURPOSE OF REVIEW: Parvovirus B19 infection is often considered a mild and self-limiting disease of minor clinical importance. This review aims to raise awareness of recently discovered potentially devastating consequences of this infection in pregnancy, and provides updated guidelines on diagnosis and management. RECENT FINDINGS: In contrast to previous beliefs, parvovirus B19 infection during any stage of pregnancy may not only cause fetal death, but may also result in severe and irreversible neurological sequelae in survivors. Improved diagnostic techniques allow more reliable and earlier diagnosis of fetal disease. SUMMARY: Clinicians need to be aware of the risk of adverse outcome of parvovirus B19 infection in pregnancy, and sometimes the long interval between exposure and fetal symptoms. Accurate diagnosis using PCR and weekly ultrasound checks ups with Doppler measurement of middle cerebral artery flow velocity up to 20 weeks postexposure may improve detection of fetal disease. More timely treatment likely results in improved outcome.